Physician profile
Brian E Tison
NPI 1255548285
$14,332.73
in general payments reported to CMS, 2019-2025
40 companies · $2,272 in 2025
The $2,272 reported for 2025 was more than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,955 · 2020: $1,891 · 2021: $2,027 · 2022: $2,225 · 2023: $1,976 · 2024: $1,987 · 2025: $2,272.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,166 · Consulting Fee: $69.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,165.88 |
| Consulting Fee | $69.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,807.21 | 2019-2025 | Fasenra, Tezspire, Airsupra |
| Csl Behring | $1,677.38 | 2019-2025 | Hizentra, Haegarda, Andembry |
| Glaxosmithkline, LLC. | $1,575.73 | 2019-2025 | Trelegy Ellipta, Nucala, Arexvy |
| Takeda Pharmaceuticals U.S.A., INC. | $1,186.43 | 2020-2025 | Cuvitru, Takhzyro, Eohilia |
| Regeneron Healthcare Solutions, INC. | $976.96 | 2019-2025 | Dupixent |
| Octapharma USA, INC. | $724.18 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $718.14 | 2019-2025 | |
| Pfizer INC. | $656.27 | 2019-2025 | |
| Optinose US, INC. | $644.05 | 2019-2024 | |
| Grifols USA, LLC | $596.52 | 2019-2025 | Xembify |
| Pharming Healthcare, INC. | $591.11 | 2019-2025 | Ruconest |
| Genzyme Corporation | $470.33 | 2019-2025 | |
| Kaleo, INC. | $374.45 | 2019-2024 | Auvi-Q |
| Amgen INC. | $273.56 | 2021-2025 | Tezspire, Actimmune |
| Biocryst US Sales Co., LLC | $252.33 | 2021-2025 | Orladeyo |
Show all 40 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $207.49 | 2019-2020 | |
| Alk-Abello, INC | $168.77 | 2019-2023 | Grastek, Odactra, Ragwitek |
| Adma Biomanufacturing LLC | $141.29 | 2020-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $124.49 | 2020-2024 | Stiolto Respimat, Spiriva Respimat |
| Galderma Laboratories, L.P. | $114.24 | 2024-2025 | Nemluvio |
| Genentech USA, INC. | $109.23 | 2019-2025 | Xolair |
| Ars Pharmaceuticals Operations, INC. | $104.93 | 2025 | Neffy |
| Ionis Pharmaceuticals, INC. | $93.63 | 2025 | Dawnzera |
| Incyte Corporation | $80.17 | 2021-2025 | Opzelura |
| Teva Pharmaceuticals USA, INC. | $78.50 | 2020-2021 | |
| Organon LLC | $71.21 | 2025 | Vtama |
| Hospira, INC. | $68.46 | 2024-2025 | |
| Abbvie INC. | $61.00 | 2022-2023 | Rinvoq |
| Shire North American Group INC | $58.49 | 2019 | |
| Novo Nordisk INC | $57.80 | 2021-2023 | |
| Biocryst Pharmaceuticals, INC. | $48.80 | 2020 | |
| Mylan Specialty L.P. | $43.05 | 2020-2022 | |
| Opko Pharmaceuticals, LLC | $35.99 | 2019-2020 | |
| Uswm, LLC | $25.00 | 2021 | |
| X4 Pharmaceuticals, INC. | $24.62 | 2024 | Xolremdi |
| Leo Pharma INC. | $22.45 | 2022 | |
| Cycle Pharmaceuticals INC | $18.88 | 2025 | Sajazir |
| Eyevance Pharmaceuticals LLC | $18.25 | 2021 | |
| Greer Laboratories, INC. | $18.00 | 2023 | Oralair |
| Sunovion Pharmaceuticals INC. | $13.34 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Tison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.